OR WAIT 15 SECS
The companies will merge to create a gene therapy biologics CDMO.
Brammer Biopharmaceuticals announced on March 31, 2016 it has merged with Florida Biologix to create a gene therapy biologics contract development and manufacturing organization (CDMO), Brammer Bio. Ampersand Capital Partners, the majority shareholder of Florida Biologix, made an additional investment in the combined company and is the only institutional investor in Brammer Bio.
Brammer Bio is focused on providing clinical and commercial supply of autologous and allogeneic cell therapies and viral vector products for in-vivo and ex-vivo therapeutic applications, along with process and analytical development and regulatory support. Brammer Bio occupies 45,000 ft2 of process development and phase I/II clinical manufacturing space in Alachua, FL, and is developing a 50,000 ft2 facility in Lexington, MA, with plans to build-out large-scale, phase III/commercial-ready viral vector manufacturing suites, segregated cell and gene therapy suites, and quality control and analytical laboratories for clinical and commercial launch services.
The management team is led by Mark Bamforth, President and CEO, and Steven Kasok, CFO, who were previously co-founders of Gallus Biopharmaceuticals, and Dr. Richard Snyder, CSO, the founder of Florida Biologix, which was spun out of the University of Florida in 2015.
Source: Brammer Bio